Abstract
Introduction
Tranexamic acid (TXA) is an antifibrinolytic agent that competitively inhibits the activation of plasminogen to plasmin. It has been shown to reduce blood loss in trauma and other haemorrhagic conditions and has recently been utilised in elective orthopaedic surgery. There are various methods of administering TXA described in the literature.
Methods
This retrospective cohort study reviews the effects of a single perioperative 1 g intravenous bolus on patients undergoing primary hip and knee arthroplasty and its effect on operative blood loss. After excluding patients who did not fulfil our inclusion criteria, a total of 110 patients were included in this study. Fifty underwent primary hip arthroplasty (30 treated with TXA; 60.0 %), and 60 underwent primary knee arthroplasty (29 treated with TXA; 48.3 %). The main outcome measure was red cell volume and total blood loss, and secondary measures were needed for blood transfusions, presence of thromboembolic events, and length of hospital stay.
Results
Both cohorts who received TXA showed a reduction in immediate postoperative red cell volume loss and total blood loss (p < 0.01). There was no association with the administration of TXA and the rate of postoperative blood transfusions (hip p = 0.36, knee p = 0.13), incidence of symptomatic deep vein thrombosis (hip p = 0.36, knee p = 0.31), or postoperative hospital length of stay (hip p = 0.70, knee p = 0.68).
Conclusion
This study demonstrates that a single perioperative bolus of intravenous TXA may significantly reduce operative blood loss in both primary total hip and knee arthroplasty in a cost-effective manner, in combination with meticulous perioperative haemostasis.
Similar content being viewed by others
References
Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, (CRASH-2 collaborators) et al (2010) Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage: a randomised, placebo-controlled trial. Lancet 376:23–32
Roberts I, Shakur H, Ker K, Coats T, (CRASH-2 collaborators) (2011) Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev 1:CD004896
Marti DN, Schaller J, Llinas M (1999) Solution structure and dynamics of the plasminogen kringle 2-AMCHA complex: 3(1)-helix in homologous domains. Biochemistry 38(48):15741–15755
Okamoto S, Hijikata-Okunomiya A, Wanaka K, Okada Y, Okamoto U (1997) Enzyme controlling medicines. Semin Thromb Hemost 23(6):493–501
Sukeik M, Alshryda S, Haddad FS, Mason JM (2001) Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg 93(1):39–46
Henry DA, Carless PA, Moxey AJ et al (2007) Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 4:CD001886
Ker K, Edwards P, Perel P, Shakur H, Roberts I (2012) Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ 344:e3054
Bradshaw AR, Monoghan J, Campbell D (2012) Oral tranexamic acid reduces blood loss in total knee replacement arthroplasty. Curr Orthop Pract 23(3):209–212
Wong J, Abrishami A, El Beheiry H, Mahomed NN, Davey JR, Gandhi R, Syed KA et al (2010) Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial. J Bone Joint Surg Am 92(15):2503–2513
Elwatidy S, Jamjoom Z, Elgamal E, Zakaria A, Turkistani A, El-Dawlatly A (2008) Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study. Spine 33(24):2577–2580
Nadler SB, Hidalgo JU, Bloch T (1962) Prediction of blood volume in normal human adults. Surgery 51:224–232
March GM, Elfatori S, Beaulé PE (2013) Clinical experience with tranexamic acid during primary total hip arthroplasty. Hip Int 23(1):72–79
Yamasaki S, Masuhara K, Fuji T (2004) Tranexamic acid reduces blood loss after cementless total hip arthroplasty—prospective randomized study in 40 cases. Int Orthop 28(2):69–73
Claeys MA, Vermeersch N, Haentjens P (2007) Reduction of blood loss with tranexamic acid in primary total hip replacement surgery. Acta Chir Belg 107:397–401
Ralley FE, Berta D, Binns V, Howard J, Naudie DDR (2010) One Intraoperative dose of tranexamic acid for patients having primary hip or knee arthroplasty. Clin Orthop Relat Res 468(7):1905–1911
MacGillivray RG, Tarabichi SA, Hawari MF, Raoof NT (2011) Tranexamic acid to reduce blood loss after bilateral total knee arthroplasty: a prospective, randomized double blind study. J Arthroplast 26(1):24–28
Benoni G, Björkman S, Fredin H (1995) Application of pharmacokinetic data from healthy volunteers for the prediction of plasma concentrations of tranexamic acid in surgical patients. Clin Drug Invest 10(5):280–287
Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL (1995) The dose−response relationship of tranexamic acid. Anesthesiology 82(2):383–392
Meda Pharmaceuticals, Cyklokapron Tablets (2013) Summary of product characteristics. Updated 3 June 2013. http://www.medicines.org.uk/. Visited 3 July 2013
Tanaka N, Sakahashi H, Sato E, Hirose K, Ishima T, Gorinbashi S, Ishii S (2001) Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee. JBJS Br 83B(5):702–705
Imai N, Dohmae Y, Suda K, Miyasaka D, Ito T, Endo N (2012) Tranexamic acid for reduction of blood loss during total hip arthroplasty. J Arthroplast 27(10):1838–1843
Benoni G, Lethagen S, Nilsson P, Fredin H (2000) Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty. Acta Orthop Scand 71(3):250–254
NHS Blood and Transplant (2013) Blood and Components. Price list. 2013/14. http://hospital.blood.co.uk/library/pdf/price_list_2013_14.pdf. Accessed 16 November 2013
BNF (British National Formulary) (2013) Tranexamic acid. BMJ Group/Royal Pharmaceutical Society of Great Britain. BMJ Publishing Group Ltd/RCPCH Publications Ltd, London
Guerriero C, Cairns J, Perel P, Shakur H, Roberts I (2011) Clinical randomization of an antifibrinolytic in significant hemorrhage 2 trial collaborators. Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial. PLoS One 6(5):e18987
Guerriero C, Cairns J, Jayaraman S, Roberts I, Perel P, Shakur H (2010) Giving tranexamic acid to reduce surgical bleeding in sub-Saharan Africa: an economic evaluation. Cost Eff Resour Alloc 8:1
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
George, D.A., Sarraf, K.M. & Nwaboku, H. Single perioperative dose of tranexamic acid in primary hip and knee arthroplasty. Eur J Orthop Surg Traumatol 25, 129–133 (2015). https://doi.org/10.1007/s00590-014-1457-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00590-014-1457-5